Organisation paid for research Program year 2025 Source: CMS Open Payments

Urban Health Plan

Neither a doctor nor a teaching hospital

Research payments

$248,309

16 payments

Through program year 2025, Urban Health Plan is reported as receiving $248,309 in research payments, across 16 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $5,545 3
2021 Research $72 2
2020 Research $67,751 2
2019 Research $174,941 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $109,721 6 payments
  2. Novartis Pharmaceuticals Corporation $105,860 6 payments
  3. AstraZeneca AB $27,183 1 payment
  4. GlaxoSmithKline, LLC. $5,545 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 52 Week Multicenter Randomized Double Blind Placebocontrolled Study to Assess the Efficacy and Safety of Qaw039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma $74,432 3 payments
  2. Forxiga HF-D1699C00001 HF rEF Outcome study $37,251 2 payments
  3. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $36,745 2 payments
  4. An Observational Primary Data Collection Study to Assess the Feasibility of Implementing the US Asthma Risk and Impairment Screener and Evaluation Navigator in Clinical Practice $32,500 1 payment
  5. A 52 Week Multicenter Randomized Double Blind Double Dummy Parallel Group Placebo Controlled Study of Fevipiprant Once Daily Plus Standard of Care Soc for Reduction of Systemic Corticosteroids Oral and Parenteral Use in Patients With Severe Asthma $31,428 3 payments
  6. A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. $27,183 1 payment
  7. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $5,545 3 payments
  8. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $3,226 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record